Rich66
11-12-2009, 07:36 PM
<!-- placeholder id=null, description=Right Region 2 --> <!-- placeholder id=null, description=Right Region 3 --> (http://informahealthcare.com/action/clickThrough?id=1184&url=http%3A%2F%2Fwww.informapharmascience.com%2Fpa ge%2FDescription%3FjournalCode%3Deop%23Instruction sForAuthors&loc=%2Fdoi%2Fabs%2F10.1517%2F17460441.3.11.1363%3F journalCode%3Dedc)<!-- placeholder id=null, description=Flash Section --> <!-- placeholder id=null, description=Banner Section 468x60 --><script type="text/javascript"><!-- // hide it from old browsers var anyDbId = -1; var sideParts = { citation: "<tr><td class=\"black9pt\" width=\"15\" valign=\"top\"> • <\/td><td class=\"black9pt\" valign=\"top\"><a href=\"javascript:newWindow('{$linkoutUrl}')\">{$display}<\/a><\/td><\/tr>", citingIsi: "<tr><td class=\"black9pt\" width=\"15\" valign=\"top\"> • <\/td><td class=\"black9pt\" valign=\"top\">Search for citing articles in:
<a href=\"javascript:newWindow('/servlet/linkout?suffix=s0&dbid=128&doi={$doi}&url={$urlEnc}')\">ISI Web of Science<\/a> ({$citNum} or more)<\/a><\/td><\/tr>", citingCrossref: "<tr><td class=\"black9pt\" width=\"15\" valign=\"top\"> • <\/td><td class=\"black9pt\" valign=\"top\"><a href=\"{$url}\">Citing articles in CrossRef<\/a><\/td><\/tr>", quicksearch: "<option value=\"{$value}\">{$display}<\/option>", related: ", <a href=\"javascript:newWindow('{$linkoutUrl}')\">{$display}<\/a>" }; function genSide(part, dbid, linkoutUrl, display, doi, url, citNum, value) { if (dbid != anyDbId && (4294967295 & dbid) == 0) return; var content = sideParts[part]; if (linkoutUrl) { content = content.replace(/{\$linkoutUrl}/g, linkoutUrl); } if (display) { content = content.replace(/{\$display}/g, display); } if (doi) { content = content.replace(/{\$doi}/g, doi); } if (url) { content = content.replace(/{\$url}/g, url); content = content.replace(/{\$urlEnc}/g, encodeURIComponent(encodeURIComponent(url))); } if (citNum) { content = content.replace(/{\$citNum}/g, citNum); } if (value) { content = content.replace(/{\$value}/g, value); } document.write(content); } function hasSfxLinks() { return false; } function genSfxLinks(id, url, doi) { } var sfxRefDisplay = { 64:"ADS", 32:"CAS", 8192:"CIS", 256:"CSA", 16:"CrossRef", 128:"ISI", 4096:"JSTOR", 8:"Medline" }; function genRefLink(dbid, id, key, textOfLink) { if (4294967295 & dbid != 0) { if (typeof textOfLink === "undefined") textOfLink = "["+sfxRefDisplay[dbid]+"]"; // ToDo: move '[' and ']' to sfxRefDisplay else textOfLink = unescape(textOfLink); document.write("<a class='ref' href=\"javascript:popRefLink("+dbid+",'"+id+"','"+key+"')\">"+textOfLink+"<\/a>"); } } function popRefLink(dbid, id, key) { var redirect = "/servlet/linkout?suffix=" + id + "&dbid=" + dbid + "&doi=10.1517%2F17460441.3.11.1363&key=" + key; return newWindow(redirect); } function popRefFull(rid, citart, ptype, area) { return popRefImplFull(rid, citart, ptype, area, 600, 500); } function popRefImplFull(rid, citart, ptype, area, width, height) { var doi = "10.1517%2F17460441.3.11.1363"; if (! ptype) { ptype = ""; } var pt = rid.charAt(0) + "174604413111363" + ptype; return popupFull(rid, doi, pt, area, width, height); } function popRef(rid, citart, ptype, area) { return popRefImpl(rid, citart, ptype, area, 600, 500); } function popRef2(rid, citart, ptype, area) { return popRefImpl(rid, citart, ptype, area, 400, 100); } function popRefImpl(rid, citart, ptype, area, width, height) { var doi = "10.1517%2F17460441.3.11.1363"; if (! citart) { citart = "citart1"; } if (! ptype) { ptype = ""; } var pt = rid.charAt(0) + "174604413111363" + ptype; return popupRef(citart, rid, doi, pt, area, width, height); } function genCitingIsi() { } function genCitingCrossref() { } var citLinkDisplay = { 0:"SYSTEM", 4:"SYSTEM", 20:"SYSTEM", 64:"ADS", 32:"CAS", 8192:"CIS", 256:"CSA", 16:"CrossRef", 128:"ISI", 4096:"JSTOR", 8:"MEDLINE" }; var feeBasedMask = 4480; function genCitLink(dbid, suffix, key) { if (dbid != anyDbId && (feeBasedMask & dbid) != 0 && (4294967295 & dbid) == 0) return; var param = "/servlet/linkout?suffix=" + suffix + "&dbid=" + dbid + "&doi=10.1517%2F17460441.3.11.1363&key=" + key; var display = citLinkDisplay[dbid]; var img = "/templates/jsp/_midtier/_ashley/images/" + display + "_btn.gif"; document.write("<a class='ref' href='javascript<b></b>:newWindow(\"" + param + "\")'>"); document.write("http://her2support.org/vbulletin/+img+"); document.write("<\/a>"); } // stop hiding --> </script> <!-- when referer is not from literatum (referer is null or not equals to the default host), display note on abstarct page --> <!-- Start title of page and review --> Summary
Expert Opinion on Drug Discovery (http://informahealthcare.com/loi/edc)
November 2008, Vol. 3, No. 11, Pages 1363-1369 , DOI 10.1517/17460441.3.11.1363
<!-- End title of page and review --> <!-- Start full text content --> <!-- abstract content -->HER dimerization inhibitors: developing pertuzumab as an anticancer agent in women's oncology
Don S Dizonhttp://informahealthcare.com/entityImage/?code=200B*<sup>†</sup><sup>1</sup> MD FACP & Sharmila Makhijahttp://informahealthcare.com/entityImage/?code=200B*<sup>2</sup> MD<sup>1</sup>Warren Alpert Medical School of Brown University, Women & Infants Hospital of Rhode Island, Program in Women's Oncology, 101 Dudley Street, RI 02905, Providence, USA +1 401 453 7520; +1 401 453 7529; ddizon@wihri.org
<sup>2</sup>Emory University, Division of Gynecologic Oncology, Department of Obstetrics-Gynecology, Atlanta, GA, USA
†http://informahealthcare.com/na101/home/literatum/publisher/ashley/journals/entities/2002.gifAuthor for correspondence
Background: Pertuzumab is a novel monoclonal antibody that blocks the dimerization domain of the human epidermal growth factor receptor (HER)-2/neu receptor, disabling its ability to form heterodimers with the other members of its family. Objective: We review the background and scientific rationale, but more specifically cover current clinical trial outcomes of pertuzumab in solid tumors, with an emphasis on the work completed in women's cancers. Methods: Clinical trial results published or presented at national meetings are included in this review. Results: Pertuzumab shows promising activity with trastuzumab in the treatment of metastatic breast cancer. The results in ovarian cancer have been limited thus far but a post hoc analysis of the results of a completed randomized Phase II trial of gemcitabine with or without pertuzumab suggests that low HER3 levels may mark a group of women who may benefit from the addition of pertuzumab to chemotherapy. Conclusions: The efficacy of pertuzumab independent of HER-2/neu overexpression remains under investigation. Still, the benefits seen in HER-2/neu positive breast cancer is encouraging. Work in ovarian cancer remains preliminary but the possibility of using pertuzumab in a targeted population with low HER3 levels warrants further evaluation.
<!-- /abstract content -->Full Text (http://informahealthcare.com/doi/full/10.1517/17460441.3.11.1363) | PDF (229 KB) (http://informahealthcare.com/doi/pdf/10.1517/17460441.3.11.1363) | PDF Plus (243 KB) (http://informahealthcare.com/doi/pdfplus/10.1517/17460441.3.11.1363)
<!-- fulltext content --><!-- /fulltext content -->
<hr> Users who read this article also read:
<table class="articleEntry" width="100%" border="0"><tbody><tr><td class="firstCell">
</td><td valign="top">Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers
Ahmad A Tarhini (http://informahealthcare.com/action/doSearch?action=runSearch&type=advanced&result=true&prevSearch=%2Bauthorsfield%3A%28Tarhini,%20Ahmad%2 0A%29), John M Kirkwood (http://informahealthcare.com/action/doSearch?action=runSearch&type=advanced&result=true&prevSearch=%2Bauthorsfield%3A%28Kirkwood,%20John%2 0M%29), Arthur M Krieg (http://informahealthcare.com/action/doSearch?action=runSearch&type=advanced&result=true&prevSearch=%2Bauthorsfield%3A%28Krieg,%20Arthur%20 M%29)Expert Opinion on Drug Discovery (http://informahealthcare.com/loi/edc), May 2009, Vol. 4, No. 5, Pages 587-603.
Summary (http://informahealthcare.com/doi/abs/10.1517/17460440902824784) | Full Text (http://informahealthcare.com/doi/full/10.1517/17460440902824784) | PDF (464 KB) (http://informahealthcare.com/doi/pdf/10.1517/17460440902824784) | PDF Plus (623 KB) (http://informahealthcare.com/doi/pdfplus/10.1517/17460440902824784) | Add to Favorites (http://informahealthcare.com/personalize/addFavoriteArticle?doi=10.1517%2F17460440902824784 ) | Related (http://informahealthcare.com/action/doSearch?doi=10.1517%2F17460440902824784&target=related) </td></tr></tbody></table>
<a href=\"javascript:newWindow('/servlet/linkout?suffix=s0&dbid=128&doi={$doi}&url={$urlEnc}')\">ISI Web of Science<\/a> ({$citNum} or more)<\/a><\/td><\/tr>", citingCrossref: "<tr><td class=\"black9pt\" width=\"15\" valign=\"top\"> • <\/td><td class=\"black9pt\" valign=\"top\"><a href=\"{$url}\">Citing articles in CrossRef<\/a><\/td><\/tr>", quicksearch: "<option value=\"{$value}\">{$display}<\/option>", related: ", <a href=\"javascript:newWindow('{$linkoutUrl}')\">{$display}<\/a>" }; function genSide(part, dbid, linkoutUrl, display, doi, url, citNum, value) { if (dbid != anyDbId && (4294967295 & dbid) == 0) return; var content = sideParts[part]; if (linkoutUrl) { content = content.replace(/{\$linkoutUrl}/g, linkoutUrl); } if (display) { content = content.replace(/{\$display}/g, display); } if (doi) { content = content.replace(/{\$doi}/g, doi); } if (url) { content = content.replace(/{\$url}/g, url); content = content.replace(/{\$urlEnc}/g, encodeURIComponent(encodeURIComponent(url))); } if (citNum) { content = content.replace(/{\$citNum}/g, citNum); } if (value) { content = content.replace(/{\$value}/g, value); } document.write(content); } function hasSfxLinks() { return false; } function genSfxLinks(id, url, doi) { } var sfxRefDisplay = { 64:"ADS", 32:"CAS", 8192:"CIS", 256:"CSA", 16:"CrossRef", 128:"ISI", 4096:"JSTOR", 8:"Medline" }; function genRefLink(dbid, id, key, textOfLink) { if (4294967295 & dbid != 0) { if (typeof textOfLink === "undefined") textOfLink = "["+sfxRefDisplay[dbid]+"]"; // ToDo: move '[' and ']' to sfxRefDisplay else textOfLink = unescape(textOfLink); document.write("<a class='ref' href=\"javascript:popRefLink("+dbid+",'"+id+"','"+key+"')\">"+textOfLink+"<\/a>"); } } function popRefLink(dbid, id, key) { var redirect = "/servlet/linkout?suffix=" + id + "&dbid=" + dbid + "&doi=10.1517%2F17460441.3.11.1363&key=" + key; return newWindow(redirect); } function popRefFull(rid, citart, ptype, area) { return popRefImplFull(rid, citart, ptype, area, 600, 500); } function popRefImplFull(rid, citart, ptype, area, width, height) { var doi = "10.1517%2F17460441.3.11.1363"; if (! ptype) { ptype = ""; } var pt = rid.charAt(0) + "174604413111363" + ptype; return popupFull(rid, doi, pt, area, width, height); } function popRef(rid, citart, ptype, area) { return popRefImpl(rid, citart, ptype, area, 600, 500); } function popRef2(rid, citart, ptype, area) { return popRefImpl(rid, citart, ptype, area, 400, 100); } function popRefImpl(rid, citart, ptype, area, width, height) { var doi = "10.1517%2F17460441.3.11.1363"; if (! citart) { citart = "citart1"; } if (! ptype) { ptype = ""; } var pt = rid.charAt(0) + "174604413111363" + ptype; return popupRef(citart, rid, doi, pt, area, width, height); } function genCitingIsi() { } function genCitingCrossref() { } var citLinkDisplay = { 0:"SYSTEM", 4:"SYSTEM", 20:"SYSTEM", 64:"ADS", 32:"CAS", 8192:"CIS", 256:"CSA", 16:"CrossRef", 128:"ISI", 4096:"JSTOR", 8:"MEDLINE" }; var feeBasedMask = 4480; function genCitLink(dbid, suffix, key) { if (dbid != anyDbId && (feeBasedMask & dbid) != 0 && (4294967295 & dbid) == 0) return; var param = "/servlet/linkout?suffix=" + suffix + "&dbid=" + dbid + "&doi=10.1517%2F17460441.3.11.1363&key=" + key; var display = citLinkDisplay[dbid]; var img = "/templates/jsp/_midtier/_ashley/images/" + display + "_btn.gif"; document.write("<a class='ref' href='javascript<b></b>:newWindow(\"" + param + "\")'>"); document.write("http://her2support.org/vbulletin/+img+"); document.write("<\/a>"); } // stop hiding --> </script> <!-- when referer is not from literatum (referer is null or not equals to the default host), display note on abstarct page --> <!-- Start title of page and review --> Summary
Expert Opinion on Drug Discovery (http://informahealthcare.com/loi/edc)
November 2008, Vol. 3, No. 11, Pages 1363-1369 , DOI 10.1517/17460441.3.11.1363
<!-- End title of page and review --> <!-- Start full text content --> <!-- abstract content -->HER dimerization inhibitors: developing pertuzumab as an anticancer agent in women's oncology
Don S Dizonhttp://informahealthcare.com/entityImage/?code=200B*<sup>†</sup><sup>1</sup> MD FACP & Sharmila Makhijahttp://informahealthcare.com/entityImage/?code=200B*<sup>2</sup> MD<sup>1</sup>Warren Alpert Medical School of Brown University, Women & Infants Hospital of Rhode Island, Program in Women's Oncology, 101 Dudley Street, RI 02905, Providence, USA +1 401 453 7520; +1 401 453 7529; ddizon@wihri.org
<sup>2</sup>Emory University, Division of Gynecologic Oncology, Department of Obstetrics-Gynecology, Atlanta, GA, USA
†http://informahealthcare.com/na101/home/literatum/publisher/ashley/journals/entities/2002.gifAuthor for correspondence
Background: Pertuzumab is a novel monoclonal antibody that blocks the dimerization domain of the human epidermal growth factor receptor (HER)-2/neu receptor, disabling its ability to form heterodimers with the other members of its family. Objective: We review the background and scientific rationale, but more specifically cover current clinical trial outcomes of pertuzumab in solid tumors, with an emphasis on the work completed in women's cancers. Methods: Clinical trial results published or presented at national meetings are included in this review. Results: Pertuzumab shows promising activity with trastuzumab in the treatment of metastatic breast cancer. The results in ovarian cancer have been limited thus far but a post hoc analysis of the results of a completed randomized Phase II trial of gemcitabine with or without pertuzumab suggests that low HER3 levels may mark a group of women who may benefit from the addition of pertuzumab to chemotherapy. Conclusions: The efficacy of pertuzumab independent of HER-2/neu overexpression remains under investigation. Still, the benefits seen in HER-2/neu positive breast cancer is encouraging. Work in ovarian cancer remains preliminary but the possibility of using pertuzumab in a targeted population with low HER3 levels warrants further evaluation.
<!-- /abstract content -->Full Text (http://informahealthcare.com/doi/full/10.1517/17460441.3.11.1363) | PDF (229 KB) (http://informahealthcare.com/doi/pdf/10.1517/17460441.3.11.1363) | PDF Plus (243 KB) (http://informahealthcare.com/doi/pdfplus/10.1517/17460441.3.11.1363)
<!-- fulltext content --><!-- /fulltext content -->
<hr> Users who read this article also read:
<table class="articleEntry" width="100%" border="0"><tbody><tr><td class="firstCell">
</td><td valign="top">Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers
Ahmad A Tarhini (http://informahealthcare.com/action/doSearch?action=runSearch&type=advanced&result=true&prevSearch=%2Bauthorsfield%3A%28Tarhini,%20Ahmad%2 0A%29), John M Kirkwood (http://informahealthcare.com/action/doSearch?action=runSearch&type=advanced&result=true&prevSearch=%2Bauthorsfield%3A%28Kirkwood,%20John%2 0M%29), Arthur M Krieg (http://informahealthcare.com/action/doSearch?action=runSearch&type=advanced&result=true&prevSearch=%2Bauthorsfield%3A%28Krieg,%20Arthur%20 M%29)Expert Opinion on Drug Discovery (http://informahealthcare.com/loi/edc), May 2009, Vol. 4, No. 5, Pages 587-603.
Summary (http://informahealthcare.com/doi/abs/10.1517/17460440902824784) | Full Text (http://informahealthcare.com/doi/full/10.1517/17460440902824784) | PDF (464 KB) (http://informahealthcare.com/doi/pdf/10.1517/17460440902824784) | PDF Plus (623 KB) (http://informahealthcare.com/doi/pdfplus/10.1517/17460440902824784) | Add to Favorites (http://informahealthcare.com/personalize/addFavoriteArticle?doi=10.1517%2F17460440902824784 ) | Related (http://informahealthcare.com/action/doSearch?doi=10.1517%2F17460440902824784&target=related) </td></tr></tbody></table>